MDRX - Allscripts upgraded to buy from hold at Goldman Sachs citing strong fundament performance

• Goldman Sachs has upgraded Allscripts Healthcare Solutions ( NASDAQ: MDRX ) to buy from hold saying that the healthcare IT solutions provider is exhibiting strong fundamental performance as it grows market share and controls costs.
• The firm upped its price target to $23 from $22 (~36% upside based on Tuesday's close).
• Analyst Cindy Motz said she expects more partnerships and acceleration in the fast growing payer and life sciences business.
• She added that the stock currently trades at an attractive valuation given its enterprise value below 7x expected FY22 EBITDA and below 8x expected FY23 EBITDA.
• Seeking Alpha's Quant Rating views Allscripts as a hold with high marks for profitability and momentum .

For further details see: